Bee Vectoring Technologies Wins International Biocontrol Manufacturers Association’s Bronze Bernard Blum Award for Biocontrol Innovation

Press Releases
Posted on October 26, 2021

Bee Vectoring Technologies Wins International Biocontrol Manufacturers Association’s Bronze Bernard Blum Award for Biocontrol Innovation

Mississauga, ON Canada and Sacramento, CA USA (October 26, 2021) – Bee Vectoring Technologies International Inc. (the “Company” or “BVT”) (CSE: BEE) (OTCQB: BEVVF) (CVE:BEE) today announced that the International Biocontrol Manufacturers Association (IBMA) has recognized BVT with the prestigious Bernard Blum Award for novel biocontrol solutions, awarding Bronze for BVT’s VectorHive™ system.

The Bernard Blum Award is presented annually for the year’s most innovative biocontrol products – those that have a high impact in pest/disease management and low impact on human health and the environment. All 230 members of the association, along with third parties, were invited to submit their most innovative solutions.

The award was presented last week in Basel, Switzerland at the 16th Annual Biocontrol Industry Meeting (ABIM) organized by the IBMA and the Research Institute of Organic Agriculture. The conference was attended by more than 970 delegates from 44 nations and 400 organizations. BVT CEO Ashish Malik and Christoph Lehnen, BVT Business Manager for Europe, Middle East and Africa attended the conference, and held meetings with 10 industry partners to advance the Company’s expansion strategy and projects. Mr. Malik also gave a presentation on the Company’s VectorHive system and Vectorite™ with CR-7 biological fungicide.

“BVT being recognized with a Bernard Blum Award is a strong indicator of the robustness and sustainability of our natural precision agriculture solution,” said Mr. Lehnen. “It emphasizes solutions with proven impact and performance in the field, not on technologies still in an experimental phase.”

Unlike conventional growing – which relies heavily on chemical pesticides prone to non-targeted exposure and high waste and requiring expensive application equipment – bee vectoring puts nature to work instead: commercially managed bees deliver BVT’s Vectorite™ with CR-7, a biological fungicide that controls fungal diseases including Colletotrichum (anthracnose), Botrytis (gray mold) and Monilinia (mummy berry).

As bees exit the hive during normal pollination activities, they walk through BVT’s VectorHive system, picking up trace amounts of the biological product (which attach harmlessly to their bodies), then carry it directly into blooms. As the bees pollinate crops, they efficiently deliver the microbe directly to where plants are most susceptible to many fungal diseases: the flower. Once on the flower, the microbe colonizes the plant and protects the crop against various diseases.

“This annual biocontrol industry meeting is an important global forum for bringing attention to and advancing the role of biocontrol for a more sustainable agricultural future,” said Mr. Malik. “Despite ongoing challenges with travel restrictions, most of the important industry players were in attendance, and we had an opportunity to meet with several very interested partners to share knowledge, explore product and market collaborations, and increase sustainable agriculture practices.”  


About
Bee Vectoring Technologies International Inc.

BVT, an agriculture technology company, is a market disruptor with a significant global market opportunity in the $240 billion crop protection and fertilizer market. BVT has pioneered a natural precision agriculture system that replaces chemical pesticides and wasteful plant protection product spray applications by delivering biological pesticide alternatives to crops using commercially grown bees. BVT’s award-winning technology, precision vectoring, is completely harmless to bees and allows minute amounts of naturally-derived pesticides (called biologicals) to be delivered directly to blooms, providing improved crop protection and yield results than traditional chemical pesticides – and improving the health of the soil, the microbiome and the environment. Currently, BVT has over 65 granted patents, over 35 patents pending in all major agricultural countries worldwide, and has US EPA registration of its Vectorite™ with CR-7 (EPA Registration No. 90641-2) for sale as a registered biological fungicide for use on the labeled crops.

Additional information can be viewed at the Company’s website www.beevt.com. To receive regular news updates from the Company, subscribe at www.beevt.com/newsletter.

Company Contact:
Ashish Malik, President & CEO
info@beevt.com

Investor Contacts:
Babak Pedram, Investor Relations
Virtus Advisory Group
Tel: 416-995-8651
bpedram@virtusadvisory.com

The CSE has neither approved nor disapproved the contents of this press release. The CSE does not accept responsibility for the adequacy or accuracy of this release. Certain statements contained in this press release constitute “forward-looking information” as such term is defined in applicable Canadian securities legislation. The words “may”, “would”, “could”, “should”, “potential”, “will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions as they relate to the Company, “annual revenue potential”, are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions, including: planted acres, selling price of competitive chemical pesticides and the US to Canadian dollar exchange rate. Material factors or assumptions were applied in providing forward-looking information. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include changes in law, competition, litigation, the ability to implement business strategies and pursue business opportunities, state of the capital markets, the availability of funds and resources to pursue operations, new technologies, the ability to protect intellectual property rights, the ability to obtain patent protection for products, third-party intellectual property infringement claims, regulatory changes affecting products, failing research and development activities, the ability to reach and sustain profitability, dependence on business and technical experts, the ability to effectively manage business operations and growth, issuance of debt, dilution of existing securities, volatility of publicly traded securities, potential conflicts of interest, unlikelihood of dividend payments, the potential costs stemming from defending third-party intellectual property infringement claims, the ability to secure relationships with manufacturers and purchasers, as well as general economic, market and business conditions, as well as those risk factors discussed or referred to in the Company’s Filing Statement dated August 14,2020, filed with the CSE and securities regulatory authorities in certain provinces of Canada and available at www.sedar.com. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law. All figures are in Canadian dollars.